Prolonged screening interval due to the COVID-19 pandemic and its association with tumor characteristics and treatment; a register-based study from BreastScreen Norway

Abstract

ObjectiveDuring the COVID-19 pandemic Norway had to suspend its national breast cancer screening program. We aimed to investigate the effect of the pandemic-induced suspension on the screening interval, and its subsequent association with the tumor characteristics and treatment of screen-detected (SDC) and interval breast cancer (IC). MethodsInformation about women aged 50–69, participating in BreastScreen Norway, and diagnosed with a SDC (N = 3799) or IC (N = 1806) between 2018 and 2021 was extracted from the Cancer Registry of Norway. Logistic regression was used to investigate the association between COVID-19 induced prolonged screening intervals and tumor characteristics and treatment. ResultsWomen with a SDC and their last screening exam before the pandemic had a median screening interval of 24.0 months (interquartile range: 23.8–24.5), compared to 27.0 months (interquartile range: 25.8–28.5) for those with their last screening during the pandemic. The tumor characteristics and treatment of women with a SDC, last screening during the pandemic, and a screening interval of 29–31 months, did not differ from those of women with a SDC, last screening before the pandemic, and a screening interval of 23–25 months. ICs detected 24–31 months after screening, were more likely to be histological grade 3 compared to ICs detected 0–23 months after screening (odds ratio: 1.40, 95% confidence interval: 1.06–1.84). ConclusionsPandemic-induced prolonged screening intervals were not associated with the tumor characteristics and treatment of SDCs, but did increase the risk of a histopathological grade 3 IC. This study provides insights into the possible effects of extending the screening interval.